echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The world's most innovative biotech company.

    The world's most innovative biotech company.

    • Last Update: 2020-08-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On May 28th, New York, Forbes released its eighth list of the world's most innovative companies, with 100 global companies on the list (see the end of the list).
    list is sorted by "innovation premium", a measure that can be used to measure which companies are best placed to convert investors' confidence in their creativity and innovation into capital.
    , seven Chinese companies are listed this year, namely Tencent Holdings (25th), Ctrip (28th), Luoyang (43rd), Baidu (45th), Hengrui Pharmaceuticals (64th), Hai Conway (90th), and China Heavy Industries (91st).
    compared with last year's list, Shanghai Leishi fell from 4th, hengrui Pharma rose from 82nd last year to 64th.
    which of the world's most innovative biotech companies are? There are nine companies on the list in pharmaceutical biotechnology and life sciences (see figure below for details).
    include five biotech companies: Incyte, Celltriona, Regeneron Pharmaceuticals, Vertex Pharmaceuticals and Ale-Pharma;
    in terms of specific rankings, the five biotech companies overall ranked in the top 25.
    Note: "Innovation premium" refers to the difference between the company's market value and the net present value of cash flows from existing businesses (based on Credit Suisse HOLT's own algorithm).
    the difference between the two is that equity investors understand the situation and expect the company to continue to achieve new growth and generate profits, thus giving the company a premium.
    , the companies on the list need seven years of financial data, with a market capitalisation of $10 billion.
    Incyte: tumor drug development small-handed, a number of new drugs ready to develop Incyte company although only experienced more than 20 years of history, but in the field of new drug development, has achieved fruitful results, in the industry has a highvisiber visibility.
    company currently has three drugs on the market: Ruxolitinib, Ponatinib and Baricitinib.
    , Ruxolitinib is the main driver of its revenue, with a net product revenue range of $1.125 to $1.135 billion in 2017, mainly due to its use in bone marrow fibrosis and erythrocyte.
    , Ruxolitinib also shows significant potential in primary platelet growth and acute/chronic transplantation of anti-host disease (GVHD).
    Incyte expects net profit to reach $2.5 billion to $3 billion in 2027.
    , the company has dozens of new products in its research line, most of them anti-tumor drugs.
    , Epacadostat is a bright spot, with the company revealing that the results of The IDO1 inhibitor epacadostat's treatment for melanoma in conjunction with Keytruda will be announced in the first half of 2018. other plans
    2018 include: mid-2018 baricitinib for the treatment of rheumatoid arthritis is expected to enter the NDA phase; Small cell lung cancer is expected to enter the NDA phase, the introduction of the PD-1 inhibitor MGA012 single drug and combination therapy clinical trials, the emergence of three new clinical candidate drugs (INCB81776, INCAGN2390 and INCAGN2385).
    Celltrion: Celltrion, a global biopharmaceutical leader, is a global biopharmaceutical company whose main business is biosimilars, new biologics and CMO.
    Celltrion bravely took the first step in developing antibody biosimilars when everyone else thought biosimilars were not yet in place.
    currently listed antibody biosimilars are REMSIMA, Herzuma (breast cancer), truxima (non-Hodge lymphoma).
    , REMSIMA is the first biosimilar drug approved by the FDA, EMA, pDMA, and more than 70 other countries, and the indications include moderate to severe active adult and pediatric Crohn's disease, moderate to severe active adult ulcerative colitis, moderate to severe active rheumatoid arthritis, severe active aggressive spinal inflammation, psoriasis arthritis, and moderate to severe block type psoriasis.
    in addition, the company's CT-P17, CT-P16, CT-P14, CT-P15, CT-P05, 5 antibody biosimilars are in development.
    in addition to the new drug layout, Celltrion has established a global marketing system with more than 20 partners, enabling its biosimilars to be available in the first place and quickly seizing the market for the original research drug.
    Regeneron: Star Products and Two Technology Platforms To Unleash Unlimited Potential Regeneron is one of the most innovative biotech companies to emerge in recent years, developing drugs primarily for the treatment of serious medical diseases.
    Regeneron's pillar star product is Eylea, the drug sales revenue can account for more than 90% of the company's total drug sales revenue, related revenue also accounted for nearly 80% of the company's overall revenue, Eylea in China in February this year, is currently the only approved for the treatment of diabetic macular edema anti-VE GF drugs.
    , regeneron has six drug products that have been fda-certified and have been eligible for the market.
    the latest DUPIXENT ® and KEVZARA ® (sarilumab) both approved FDA listings this year, and will bear the burden of Regeneron's sales growth and profit creation over the next few years.
    it's worth noting that Regeneron, with its two technology platforms, Trap and Veloc Immune, has taken its own path in the competition, reducing the cost of developing each new drug to the lowest level in the industry, averaging just $736 million per drug.
    Vertex: Vertex, which focuses on innovation in the CF field, has absolute voice and pricing power, has an absolute say in the field of cystic fibrosis (CF), and two products have been approved for the market.
    's first product, Kalydeco (ivacaftor), was approved in 2012 as the world's first CF-targeted treatment drug for CF patients with different CFTR mutations, and the second, Orkambi (lumacaftor/ivacaftor), was introduced in 2015 for patients with two copies of F508 dystor's.
    at this stage, Vertex is working on a combination of tezacaftor/ivacaftor for patients 12 years and older who carry 2 copies of F508del mutation or carry one F508del mutation and one residual CFTR function mutation.
    currently, tezacaftor/ivacaftor combination therapy is under review by US and EU regulators.
    , if approved, the combination will be Vertex's third treatment for CF and will provide a very important new treatment option for the CF patient population.
    in addition to tezacaftor/ivacaftor, Vertex has several CF triple therapies that are clinically developed in the late-middle stages.
    at the end of August, Wall Street predicted four biotech stocks that would grow rapidly over the next four years, and Vertex was shortlisted.
    , thanks to the diversity of CF gene mutations and the lack of competition in the market, Vertex has an absolute voice and pricing power in the CF field.
    Wall Street Consensus forecasts that full-year sales of the company's CF products will grow from $1.7 billion to $4.1 billion between 2016 and 2020, with a COMPOUND annual growth rate of 68 percent over the next four years.
    Aledrug Pharmaceuticals, headquartered in Connecticut, IS, is one of the world's leading research and development companies for rare diseases, based in Connecticut, USA, inc.
    Alexion's "Home Flower" is the rare disease drug Soliris (eculizumab), known as the "world's most expensive drug" for the treatment of blood diseases that cause organ failure - atypical hemolytic uremia syndrome (aHUS) and pneumoconiosis hemoglobinuria (PNH).
    sales of the drug in 2017 amounted to US$3.144 billion, accounting for 88.53 percent of the company's annual sales, and global drug sales TOP50.
    However, Soliris' U.S. patent expires in 2027, and in the face of competition from similar and innovative drugs, Alexion is re-creating the Soliris long-lasting version, ALXN1210, which is expected to extend the patent until 2035.
    it is understood that in the most recent financial year 2018 first quarter results, Alexion company published ALXN1210 Phase 2 3 clinical data, ALXN1210 compared to Soliris is not inferior, but the effectiveness is not obvious. In addition,
    , Alepharmaceutical has been expanding its research and development pipeline through acquisitions, including acquiring Enobian inc. for Strensiq in 2011, acquiring Synageva for $8.4 billion in June 2015, and acquiring The sydment of WT Disease's new drug X101 in April 2018 for $855 million.
    Source: Pharmaceutical Intelligence Network.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.